C
Carnyx Therapeutics develops novel therapeutics aimed at improving human healthspan and longevity. The company's pipeline includes CNYX-001, a gene-independent eye-drop therapy targeting Retinitis Pigmentosa, and CNYX-005 for sleep disorders. These molecular assets are designed to address chronic diseases, enhance vitality, and slow retinal degeneration.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Carnyx Therapeutics develops novel therapeutics aimed at improving human healthspan and longevity. The company's pipeline includes CNYX-001, a gene-independent eye-drop therapy targeting Retinitis Pigmentosa, and CNYX-005 for sleep disorders. These molecular assets are designed to address chronic diseases, enhance vitality, and slow retinal degeneration.